Jump to content

Inactivated vaccine: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
Clinger0 (talk | contribs)
27 edits
m two more sources
this source does not exist
Line 23: Line 23:
An '''inactivated vaccine''' (or '''killed vaccine''') is a type of [[vaccine]] that contains pathogens (such as [[virus]] or [[bacteria]]) that have been killed or rendered inactive, so they cannot replicate or cause disease. In contrast, [[attenuated vaccine|live vaccines]] use pathogens that are still alive (but are almost always [[attenuated vaccine|attenuated]], that is, weakened). Pathogens for inactivated vaccines are grown under controlled conditions and are killed as a means to reduce infectivity and thus prevent [[infection]] from the vaccine.<ref name="PetrovskyAguilar2004">{{cite journal | vauthors = Petrovsky N, Aguilar JC | title = Vaccine adjuvants: current state and future trends | journal = Immunology and Cell Biology | volume = 82 | issue = 5 | pages = 488–496 | date = October 2004 | pmid = 15479434 | doi = 10.1111/j.0818-9641.2004.01272.x | s2cid = 154670 }}</ref>
An '''inactivated vaccine''' (or '''killed vaccine''') is a type of [[vaccine]] that contains pathogens (such as [[virus]] or [[bacteria]]) that have been killed or rendered inactive, so they cannot replicate or cause disease. In contrast, [[attenuated vaccine|live vaccines]] use pathogens that are still alive (but are almost always [[attenuated vaccine|attenuated]], that is, weakened). Pathogens for inactivated vaccines are grown under controlled conditions and are killed as a means to reduce infectivity and thus prevent [[infection]] from the vaccine.<ref name="PetrovskyAguilar2004">{{cite journal | vauthors = Petrovsky N, Aguilar JC | title = Vaccine adjuvants: current state and future trends | journal = Immunology and Cell Biology | volume = 82 | issue = 5 | pages = 488–496 | date = October 2004 | pmid = 15479434 | doi = 10.1111/j.0818-9641.2004.01272.x | s2cid = 154670 }}</ref>


Inactivated vaccines were first developed in the late 1800s and early 1900s for [[Cholera vaccine|cholera]], [[Plague vaccine|plague]], and [[Typhoid vaccine|typhoid]].<ref name="VaccPastFuture2011">{{cite journal | vauthors = Plotkin SA, Plotkin SL | title = The development of vaccines: how the past led to the future | journal = Nature Reviews. Microbiology | volume = 9 | issue = 12 | pages = 889–893 | date = October 2011 | pmid = 21963800 | doi = 10.1038/nrmicro2668 | s2cid = 32506969 | publication-date = 2011-10-03 | doi-access = free }}</ref> In 1897, Japanese scientists developed an inactivated vaccine for the bubonic plague. In the 1950's, [[Jonas Salk]] created an inactivated vaccine for the poliovirus, creating the first vaccine that was both safe and effective against [[polio]]. Today, inactivated vaccines exist for many pathogens, including [[Influenza vaccine|influenza]], [[Polio vaccine|polio]] (IPV), [[Rabies vaccine|rabies]], [[Hepatitis A vaccine|hepatitis A]], [[CoronaVac]], [[Covaxin]] and [[Pertussis vaccine|pertussis]].<ref name="CDCPinkBook2021Ch1">{{cite book | vauthors = Wodi AP, Morelli V |chapter=Chapter 1: Principles of Vaccination |chapter-url=https://www.cdc.gov/vaccines/pubs/pinkbook/downloads/prinvac.pdf | veditors = Hall E, Wodi AP, Hamborsky J, Morelli V, Schilllie S |title=Epidemiology and Prevention of Vaccine-Preventable Diseases | url=https://www.cdc.gov/vaccines/pubs/pinkbook/index.html |location=Washington, D.C.|publisher=Public Health Foundation, Centers for Disease Control and Prevention|year=2021 |edition=14th }}</ref><ref>{{Cite book |last=Brown |first=Jonathan |title=The History of Medicine: A Scandalously Short Introduction |date=1997 |publisher=W.W. Norton & Company |year=1997 |isbn=978-0-393-31611-7 |edition=1st |publication-date=1997 |pages=1-530 |language=en}}</ref><ref>{{Cite journal |last=Hilleman |first=Maurice |date=April 1987 |title=Vaccines and the Eradication of Poliomyelitis. |journal=The Journal of Infectious Diseases |volume=155 |issue=4 |pages=509-529 |via=PubMed, JSTOR, Oxford Academic, Elsevier ScienceDirect}}</ref>
Inactivated vaccines were first developed in the late 1800s and early 1900s for [[Cholera vaccine|cholera]], [[Plague vaccine|plague]], and [[Typhoid vaccine|typhoid]].<ref name="VaccPastFuture2011">{{cite journal | vauthors = Plotkin SA, Plotkin SL | title = The development of vaccines: how the past led to the future | journal = Nature Reviews. Microbiology | volume = 9 | issue = 12 | pages = 889–893 | date = October 2011 | pmid = 21963800 | doi = 10.1038/nrmicro2668 | s2cid = 32506969 | publication-date = 2011-10-03 | doi-access = free }}</ref> In 1897, Japanese scientists developed an inactivated vaccine for the bubonic plague. In the 1950's, [[Jonas Salk]] created an inactivated vaccine for the poliovirus, creating the first vaccine that was both safe and effective against [[polio]]. Today, inactivated vaccines exist for many pathogens, including [[Influenza vaccine|influenza]], [[Polio vaccine|polio]] (IPV), [[Rabies vaccine|rabies]], [[Hepatitis A vaccine|hepatitis A]], [[CoronaVac]], [[Covaxin]] and [[Pertussis vaccine|pertussis]].<ref name="CDCPinkBook2021Ch1">{{cite book | vauthors = Wodi AP, Morelli V |chapter=Chapter 1: Principles of Vaccination |chapter-url=https://www.cdc.gov/vaccines/pubs/pinkbook/downloads/prinvac.pdf | veditors = Hall E, Wodi AP, Hamborsky J, Morelli V, Schilllie S |title=Epidemiology and Prevention of Vaccine-Preventable Diseases | url=https://www.cdc.gov/vaccines/pubs/pinkbook/index.html |location=Washington, D.C.|publisher=Public Health Foundation, Centers for Disease Control and Prevention|year=2021 |edition=14th }}</ref><ref>{{Cite book |last=Brown |first=Jonathan |title=The History of Medicine: A Scandalously Short Introduction |date=1997 |publisher=W.W. Norton & Company |year=1997 |isbn=978-0-393-31611-7 |edition=1st |publication-date=1997 |pages=1-530 |language=en}}</ref>


Because inactivated pathogens tend to produce a weaker response by the immune system than live pathogens, [[immunologic adjuvant]]s and multiple "[[Booster injection|booster]]" injections may be required in some vaccines to provide an effective immune response against the pathogen.<ref name=PetrovskyAguilar2004/><ref name="WHOinfluenza">{{cite web|last1=WHO Expert Committee on Biological Standardization|title=Influenza|url=https://www.who.int/teams/health-product-and-policy-standards/standards-and-specifications/vaccine-standardization/influenza|publisher=World Health Organization (WHO)|date=19 June 2019|access-date=22 October 2021}}</ref><ref name="TypesVaccines">{{cite web|title=Types of Vaccines|url=http://www.vaccines.gov/more_info/types/|website=Vaccines.gov|publisher=U.S. Department of Health and Human Services|access-date=16 May 2016|date=23 July 2013|archive-url=https://web.archive.org/web/20130609071759/http://www.vaccines.gov/more_info/types|archive-date=9 June 2013|url-status=dead}}</ref> Attenuated vaccines are often preferable for generally healthy people because a single dose is often safe and very effective. However, some people cannot take attenuated vaccines because the pathogen poses too much risk for them (for example, [[old age|elderly people]] or people with [[immunodeficiency]]). For those patients, an inactivated vaccine can provide protection.{{cn|date=July 2023}}
Because inactivated pathogens tend to produce a weaker response by the immune system than live pathogens, [[immunologic adjuvant]]s and multiple "[[Booster injection|booster]]" injections may be required in some vaccines to provide an effective immune response against the pathogen.<ref name=PetrovskyAguilar2004/><ref name="WHOinfluenza">{{cite web|last1=WHO Expert Committee on Biological Standardization|title=Influenza|url=https://www.who.int/teams/health-product-and-policy-standards/standards-and-specifications/vaccine-standardization/influenza|publisher=World Health Organization (WHO)|date=19 June 2019|access-date=22 October 2021}}</ref><ref name="TypesVaccines">{{cite web|title=Types of Vaccines|url=http://www.vaccines.gov/more_info/types/|website=Vaccines.gov|publisher=U.S. Department of Health and Human Services|access-date=16 May 2016|date=23 July 2013|archive-url=https://web.archive.org/web/20130609071759/http://www.vaccines.gov/more_info/types|archive-date=9 June 2013|url-status=dead}}</ref> Attenuated vaccines are often preferable for generally healthy people because a single dose is often safe and very effective. However, some people cannot take attenuated vaccines because the pathogen poses too much risk for them (for example, [[old age|elderly people]] or people with [[immunodeficiency]]). For those patients, an inactivated vaccine can provide protection.{{cn|date=July 2023}}

Revision as of 00:48, 23 November 2024

Inactivated vaccine
Typhoid prophylaxis for soldiers in World War I.
Other namesKilled vaccine Non-replicating vaccines
SpecialtyPublic health, immunology, family medicine, general practice
Usesprevention of infectious diseases
Frequencybirth to adulthood
See also: Vaccination schedule and Vaccination policy § By country
Outcomesdevelopment of active immunity in individuals; contribution to herd immunity

An inactivated vaccine (or killed vaccine) is a type of vaccine that contains pathogens (such as virus or bacteria) that have been killed or rendered inactive, so they cannot replicate or cause disease. In contrast, live vaccines use pathogens that are still alive (but are almost always attenuated, that is, weakened). Pathogens for inactivated vaccines are grown under controlled conditions and are killed as a means to reduce infectivity and thus prevent infection from the vaccine.[1]

Inactivated vaccines were first developed in the late 1800s and early 1900s for cholera, plague, and typhoid.[2] In 1897, Japanese scientists developed an inactivated vaccine for the bubonic plague. In the 1950's, Jonas Salk created an inactivated vaccine for the poliovirus, creating the first vaccine that was both safe and effective against polio. Today, inactivated vaccines exist for many pathogens, including influenza, polio (IPV), rabies, hepatitis A, CoronaVac, Covaxin and pertussis.[3][4]

Because inactivated pathogens tend to produce a weaker response by the immune system than live pathogens, immunologic adjuvants and multiple "booster" injections may be required in some vaccines to provide an effective immune response against the pathogen.[1][5][6] Attenuated vaccines are often preferable for generally healthy people because a single dose is often safe and very effective. However, some people cannot take attenuated vaccines because the pathogen poses too much risk for them (for example, elderly people or people with immunodeficiency). For those patients, an inactivated vaccine can provide protection.[citation needed]

Mechanism

The pathogen particles are destroyed and cannot divide, but the pathogens maintain some of their integrity to be recognized by the immune system and evoke an adaptive immune response.[7][8] When manufactured correctly, the vaccine is not infectious, but improper inactivation can result in intact and infectious particles.[citation needed]

When a vaccine is administered, the antigen will be taken up by an antigen-presenting cell (APC) and transported to a draining lymph node in vaccinated people. The APC will place a piece of the antigen, an epitope, on its surface along with a major histocompatibility complex (MHC) molecule. It can now interact with and activate T cells. The resulting helper T cells will then stimulate an antibody-mediated or cell-mediated immune response and develop an antigen-specific adaptive response.[9][10] This process creates an immunological memory against the specific pathogen and allows the immune system to respond more effectively and rapidly after subsequent encounters with that pathogen.[7][9][10]

Inactivated vaccines tend to produce an immune response that is primarily antibody-mediated.[3][11] However, deliberate adjuvant selection allows inactivated vaccines to stimulate a more robust cell-mediated immune response.[1][8]

Social Consequences

The use of inactivated vaccines helped reduce morbidity and mortality from diseases like tetanus, diphtheria, and pertussis, creating a healthier, more stable society. Community health improved as a result, particularly in developed nations, where high vaccination rates led to herd immunity.[12][13]

Reducing diseases like polio, hepatitis A, and influenza meant fewer people suffering from debilitating illness, which in turn led to increased social productivity. Families no longer had to care for loved ones with debilitating diseases, and children could go to school without the constant fear of contraction. Inactivated vaccines increased public trust in public health systems, normalizing vaccinations to the point where yearly flu shots and childhood immunization are seen as routine parts of life, especially in developed countries.[12][13]

Types

Inactivated vaccines can be divided by the method used for killing the pathogen.[5][1]

A minority of sources use the term inactivated vaccines to broadly refer to non-live vaccines. Under this definition, inactivated vaccines also include subunit vaccines and toxoid vaccines.[3][9]

Examples

Types include:[18]

Advantages and disadvantages

Advantages

  • Inactivated pathogens are more stable than live pathogens. Increased stability facilitates the storage and transport of inactivated vaccines.[9][19][20]
  • Unlike live attenuated vaccines, inactivated vaccines cannot revert to a virulent form and cause disease.[7][11] For example, there have been rare instances of the live attenuated form of poliovirus present in the oral polio vaccine (OPV) becoming virulent, leading to the inactivated polio vaccine (IPV) replacing OPV in many countries with controlled wild-type polio transmission.[7][10]
  • Unlike live attenuated vaccines, inactivated vaccines do not replicate and are not contraindicated for immunocompromised individuals.[7][8][9][21][22]

Disadvantages

  • Inactivated vaccines have a reduced ability to produce a robust immune response for long-lasting immunity when compared to live attenuated vaccines.[3] Adjuvants and boosters are often required to produce and maintain protective immunity.[11][19]
  • Pathogens must be cultured and inactivated for the creation of killed whole-organism vaccines.[7][10] This process slows down vaccine production when compared to genetic vaccines.[9]
  • Inactivated vaccines tend to produce less durable immunity, often requiring multiple doses, which can pose a public health challenge. For example, the flu vaccine requires annual updates and re-administration, and hepatitis A vaccines often require two doses spaced six months apart.

References

  1. ^ a b c d Petrovsky N, Aguilar JC (October 2004). "Vaccine adjuvants: current state and future trends". Immunology and Cell Biology. 82 (5): 488–496. doi:10.1111/j.0818-9641.2004.01272.x. PMID 15479434. S2CID 154670.
  2. ^ Plotkin SA, Plotkin SL (October 2011). "The development of vaccines: how the past led to the future". Nature Reviews. Microbiology. 9 (12) (published 2011-10-03): 889–893. doi:10.1038/nrmicro2668. PMID 21963800. S2CID 32506969.
  3. ^ a b c d Wodi AP, Morelli V (2021). "Chapter 1: Principles of Vaccination" (PDF). In Hall E, Wodi AP, Hamborsky J, Morelli V, Schilllie S (eds.). Epidemiology and Prevention of Vaccine-Preventable Diseases (14th ed.). Washington, D.C.: Public Health Foundation, Centers for Disease Control and Prevention.
  4. ^ Brown, Jonathan (1997). The History of Medicine: A Scandalously Short Introduction (1st ed.). W.W. Norton & Company. pp. 1–530. ISBN 978-0-393-31611-7.{{cite book}}: CS1 maint: date and year (link)
  5. ^ a b c WHO Expert Committee on Biological Standardization (19 June 2019). "Influenza". World Health Organization (WHO). Retrieved 22 October 2021.
  6. ^ a b "Types of Vaccines". Vaccines.gov. U.S. Department of Health and Human Services. 23 July 2013. Archived from the original on 9 June 2013. Retrieved 16 May 2016.
  7. ^ a b c d e f Vetter V, Denizer G, Friedland LR, Krishnan J, Shapiro M (March 2018). "Understanding modern-day vaccines: what you need to know". Annals of Medicine. 50 (2): 110–120. doi:10.1080/07853890.2017.1407035. PMID 29172780. S2CID 25514266.
  8. ^ a b c Slifka MK, Amanna I (May 2014). "How advances in immunology provide insight into improving vaccine efficacy". Vaccine. 32 (25): 2948–2957. doi:10.1016/j.vaccine.2014.03.078. PMC 4096845. PMID 24709587.
  9. ^ a b c d e f Pollard AJ, Bijker EM (February 2021). "A guide to vaccinology: from basic principles to new developments". Nature Reviews. Immunology. 21 (2): 83–100. doi:10.1038/s41577-020-00479-7. PMC 7754704. PMID 33353987.
  10. ^ a b c d Karch CP, Burkhard P (November 2016). "Vaccine technologies: From whole organisms to rationally designed protein assemblies". Biochemical Pharmacology. 120: 1–14. doi:10.1016/j.bcp.2016.05.001. PMC 5079805. PMID 27157411.
  11. ^ a b c Plotkin S, Orenstein WA, Offit PA, eds. (2018). "Technologies for Making New Vaccines". Plotkin's vaccines (7th ed.). Philadelphia, PA: Elsevier. ISBN 978-0-323-39302-7. OCLC 989157433.
  12. ^ a b Oshinsky, David (April 21, 2005). Polio: An American Story (1st ed.). Oxford University Press. ISBN 978-0-19-515294-4.{{cite book}}: CS1 maint: date and year (link)
  13. ^ a b "Johns Hopkins Bloomberg School of Public Health". publichealth.jhu.edu. Retrieved 2024-11-22.
  14. ^ Sanders B, Koldijk M, Schuitemaker H (2015). "Inactivated Viral Vaccines". Vaccine Analysis: Strategies, Principles, and Control. pp. 45–80. doi:10.1007/978-3-662-45024-6_2. ISBN 978-3-662-45023-9. PMC 7189890. S2CID 81212732.
  15. ^ Hotez, Peter J.; Bottazzi, Maria Elena (27 January 2022). "Whole Inactivated Virus and Protein-Based COVID-19 Vaccines". Annual Review of Medicine. 73 (1): 55–64. doi:10.1146/annurev-med-042420-113212. ISSN 0066-4219. PMID 34637324. S2CID 238747462.
  16. ^ Chen J, Wang J, Zhang J, Ly H (2021). "Advances in Development and Application of Influenza Vaccines". Frontiers in Immunology. 12: 711997. doi:10.3389/fimmu.2021.711997. PMC 8313855. PMID 34326849.
  17. ^ National Advisory Committee on Immunization (NACI) (May 2018). NACI literature review on the comparative effectiveness and immunogenicity of subunit and split virus inactivated influenza vaccines in adults 65 years of age and older. ISBN 9780660264387. Cat.: HP40-213/2018E-PDF; Pub.: 180039. {{cite book}}: |website= ignored (help)
  18. ^ Ghaffar A, Haqqi T. "Immunization". Immunology. The Board of Trustees of the University of South Carolina. Archived from the original on 26 February 2014. Retrieved 2009-03-10.
  19. ^ a b Clem AS (January 2011). "Fundamentals of vaccine immunology". Journal of Global Infectious Diseases. 3 (1): 73–78. doi:10.4103/0974-777X.77299. PMC 3068582. PMID 21572612.
  20. ^ "Inactivated whole-cell (killed antigen) vaccines - WHO Vaccine Safety Basics". vaccine-safety-training.org. World Health Organization (WHO). Retrieved 2021-11-11.
  21. ^ "Influenza (Flu) Vaccination: Questions and Answers". CDC (Centers for Disease Control and Prevention). 2022. Retrieved November 21, 2024. {{cite web}}: |first= missing |last= (help)CS1 maint: url-status (link)
  22. ^ Glezen, Couch, Paul, Robert (August 19, 2004). "Vaccination against influenza in healthy adults". New England Journal of Medicine (NEJM). Retrieved November 21, 2024.{{cite web}}: CS1 maint: multiple names: authors list (link) CS1 maint: url-status (link)
Retrieved from "https://en.wikipedia.org/enwiki/w/index.php?title=Inactivated_vaccine&oldid=1259033883"